KLK14

KLK14
식별자
에일리어스	KLK14, KLK-L6, 칼리크레인관련펩티드가수분해효소14
외부 ID	OMIM: 606135 MGI: 2447564 HomoloGene: 69348 GeneCard: KLK14
유전자 위치(인간)
크르.	19번 염색체(인간)
끝.	51,084,245 bp
유전자 위치(마우스)
크르.	7번 염색체(쥐)
끝.	43,344,960 bp
RNA발현패턴
	상단 표시 위치:
	복부 피부; ; 좌심실; ; 질; ; 미산핵; ; 창호; ; 침샘; ; 소침샘; ; 췌장체; ; 위체; ; 우측 자궁관;
	상단 표시 위치:
	식도; ; 입술; ; 모룰라; ; 이차 난모세포; ; 골수; ; 백색 지방 조직; ; 피부대; ; 폐; ; 배; ; 후구;
	추가 참조 표현식 데이터
	추가 참조 표현식 데이터
유전자 존재론
분자 함수	펩티드가수분해효소활성; 세린형펩티드가수분해효소활성; 세린형 엔도펩티드가수분해효소활성; 가수분해효소활성;
셀룰러 컴포넌트	세포외 영역; 세포외 공간; 분비 과립;
생물학적 과정	수정; 표피 형태 형성; 정응고 액상화; G단백질결합수용체신호경로양조절; G단백질결합수용체신호경로음성조절; 단백질 분해; 옥수수화;
	출처:아미고 / QuickGO
맞춤법
	43847
	317653
	ENSG00000129437
	ENSMUSG000044737
	Q9P0G3
	Q8CGR5
	NM_001311182; NM_022046; NM_001369775
	NM_174866
	NP_001298111; NP_071329; NP_001356704
	NP_777355
	위키데이터
인간 보기/편집	마우스 표시/편집

Kallikrein-14는 KLK14 유전자에 ^[5]^[6]^[7]의해 인간에게 암호화되는 단백질이다.

칼리크레인(Kallikreins)은 다양한 생리 기능을 가진 세린 단백질 분해 효소의 하위 그룹이다.늘어나는 증거는 많은 칼리크레인들이 발암에 관여하고 있고 일부는 새로운 암, 피부 장애,^[8] 그리고 다른 질병 바이오마커로서의 가능성을 가지고 있다는 것을 암시한다.이 유전자는 19번 염색체의 클러스터에 위치한 15개의 칼리크레인 아족 중 하나이다.일반적인 대본과는 별도로, 추가적인 대본 변형이 설명되었지만, 기능과 전체 길이의 ^[7]성격의 차이는 결정되지 않았다.

KLK14는 알칼리성 pH 8.0에서 최적의 트립신 유사 활성을 나타내며 pH 5.0~9.0에서 활성 상태를 유지하며 자이모겐으로 생성되지만 키모트립신 유사 ^[9]활성을 나타낼 수도 있다.KLK14의 활성화는 KLK5에 의해 매개되며, KLK14 활성화 후에는 KLK ^[10]^[11]캐스케이드 내 중심 플레이어인 프로K5의 분열을 통해 정피드백 루프로 KLK 단백질 분해효소의 활성을 더욱 증폭시킨다.KLK14의 기능은 아직 완전히 설명되지 않았지만 가장 주목할 만한 기판은 PAR2이다.^[12]^[13]그 활성은 매크로글로불린, 세르핀 및 세린 단백질 분해효소 억제제 림프오-상피 카잘-관련 억제제(LEKTI) 및 미세 환경 pH와 ^[14]같은 다양한 단백질과 KLKs의 단일 금속 이온 억제제에 의해 억제된다.

레퍼런스

^ ^a ^b ^c GRCh38: 앙상블 릴리즈 89: ENSG00000129437 - 앙상블, 2017년 5월
^ ^a ^b ^c GRCm38: 앙상블 릴리즈 89: ENSMUSG000044737 - 앙상블, 2017년 5월
^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^ Lundwall A, Band V, Blaber M, Clements JA, Courty Y, Diamandis EP, et al. (June 2006). "A comprehensive nomenclature for serine proteases with homology to tissue kallikreins". Biological Chemistry. 387 (6): 637–41. doi:10.1515/BC.2006.082. PMID 16800724. S2CID 436200.
^ "Proceedings of the 1st International Symposium on Kallikreins, Lausanne, Switzerland, September 1-3 , 2005". Biological Chemistry. 387 (6): 635–824. June 2006. doi:10.1515/BC.2006.081. PMID 16800723. S2CID 83910246.
^ ^a ^b "Entrez Gene: KLK14 kallikrein-related peptidase 14".
^ Prassas I, Eissa A, Poda G, Diamandis EP (March 2015). "Unleashing the therapeutic potential of human kallikrein-related serine proteases". Nature Reviews. Drug Discovery. 14 (3): 183–202. doi:10.1038/nrd4534. PMID 25698643. S2CID 38090565.
^ Emami N, Diamandis EP (December 2007). "New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family". Molecular Oncology. 1 (3): 269–87. doi:10.1016/j.molonc.2007.09.003. PMC 5543873. PMID 19383303.
^ Brattsand M, Stefansson K, Lundh C, Haasum Y, Egelrud T (January 2005). "A proteolytic cascade of kallikreins in the stratum corneum". The Journal of Investigative Dermatology. 124 (1): 198–203. doi:10.1111/j.0022-202x.2004.23547.x. PMID 15654974.
^ Eissa A, Diamandis EP (June 2008). "Human tissue kallikreins as promiscuous modulators of homeostatic skin barrier functions". Biological Chemistry. 389 (6): 669–80. doi:10.1515/bc.2008.079. PMID 18627299. S2CID 30602024.
^ Hachem JP, Man MQ, Crumrine D, Uchida Y, Brown BE, Rogiers V, et al. (September 2005). "Sustained serine proteases activity by prolonged increase in pH leads to degradation of lipid processing enzymes and profound alterations of barrier function and stratum corneum integrity". The Journal of Investigative Dermatology. 125 (3): 510–20. doi:10.1111/j.0022-202x.2005.23838.x. PMID 16117792.
^ Hachem JP, Wagberg F, Schmuth M, Crumrine D, Lissens W, Jayakumar A, et al. (July 2006). "Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome". The Journal of Investigative Dermatology. 126 (7): 1609–21. doi:10.1038/sj.jid.5700288. PMID 16601670.
^ Swedberg JE, Veer SJ, Harris JM (2012). "Natural, engineered and synthetic inhibitors of kallikrein-related peptidases.". In Magdolen V, Sommerhoff CP, Fritz H, Schmitt M (eds.). Kallikrein-Related Peptidases. Vol. 1: Characterization, regulation, and interactions within the proteas e. Walter de Gruyter GmbH. pp. 141–160. doi:10.1515/9783110260373.141. ISBN 978-3-11-026037-3.

추가 정보

Harvey TJ, Hooper JD, Myers SA, Stephenson SA, Ashworth LK, Clements JA (December 2000). "Tissue-specific expression patterns and fine mapping of the human kallikrein (KLK) locus on proximal 19q13.4". The Journal of Biological Chemistry. 275 (48): 37397–406. doi:10.1074/jbc.M004525200. PMID 10969073.
Yousef GM, Magklara A, Chang A, Jung K, Katsaros D, Diamandis EP (April 2001). "Cloning of a new member of the human kallikrein gene family, KLK14, which is down-regulated in different malignancies". Cancer Research. 61 (8): 3425–31. PMID 11309303.
Hooper JD, Bui LT, Rae FK, Harvey TJ, Myers SA, Ashworth LK, Clements JA (April 2001). "Identification and characterization of KLK14, a novel kallikrein serine protease gene located on human chromosome 19q13.4 and expressed in prostate and skeletal muscle". Genomics. 73 (1): 117–22. doi:10.1006/geno.2000.6490. PMID 11352573.
Yousef GM, Borgoño CA, Scorilas A, Ponzone R, Biglia N, Iskander L, et al. (November 2002). "Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis". British Journal of Cancer. 87 (11): 1287–93. doi:10.1038/sj.bjc.6600623. PMC 2408908. PMID 12439719.
Yousef GM, Stephan C, Scorilas A, Ellatif MA, Jung K, Kristiansen G, et al. (September 2003). "Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues". The Prostate. 56 (4): 287–92. doi:10.1002/pros.10263. PMID 12858357.
Brattsand M, Stefansson K, Lundh C, Haasum Y, Egelrud T (January 2005). "A proteolytic cascade of kallikreins in the stratum corneum". The Journal of Investigative Dermatology. 124 (1): 198–203. doi:10.1111/j.0022-202X.2004.23547.x. PMID 15654974.
Felber LM, Borgoño CA, Cloutier SM, Kündig C, Kishi T, Ribeiro Chagas J, et al. (March 2005). "Enzymatic profiling of human kallikrein 14 using phage-display substrate technology". Biological Chemistry. 386 (3): 291–8. doi:10.1515/BC.2005.035. PMID 15843175. S2CID 22540263.
Fritzsche F, Gansukh T, Borgoño CA, Burkhardt M, Pahl S, Mayordomo E, et al. (February 2006). "Expression of human Kallikrein 14 (KLK14) in breast cancer is associated with higher tumour grades and positive nodal status". British Journal of Cancer. 94 (4): 540–7. doi:10.1038/sj.bjc.6602956. PMC 2361186. PMID 16434994.
Stefansson K, Brattsand M, Ny A, Glas B, Egelrud T (June 2006). "Kallikrein-related peptidase 14 may be a major contributor to trypsin-like proteolytic activity in human stratum corneum". Biological Chemistry. 387 (6): 761–8. doi:10.1515/BC.2006.095. PMID 16800737. S2CID 42907424.
Borgoño CA, Michael IP, Shaw JL, Luo LY, Ghosh MC, Soosaipillai A, et al. (January 2007). "Expression and functional characterization of the cancer-related serine protease, human tissue kallikrein 14". The Journal of Biological Chemistry. 282 (4): 2405–22. doi:10.1074/jbc.M608348200. PMID 17110383.
Borgoño CA, Michael IP, Komatsu N, Jayakumar A, Kapadia R, Clayman GL, et al. (February 2007). "A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation". The Journal of Biological Chemistry. 282 (6): 3640–52. doi:10.1074/jbc.M607567200. PMID 17158887.

외부 링크

펩티드가수분해효소 및 그 억제제에 대한 MEROPS 온라인 데이터베이스: S01.029

인간 염색체 19번 유전자에 대한 이 기사는 짧은 글이다.위키피디아를 확장함으로써 위키피디아를 도울 수 있습니다.

[refGRCh38Ensembl-1] GRCh38: 앙상블 릴리즈 89: ENSG00000129437 - 앙상블, 2017년 5월

[refGRCm38Ensembl-2] GRCm38: 앙상블 릴리즈 89: ENSMUSG000044737 - 앙상블, 2017년 5월

[3] "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.

[4] "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.

[pmid16800724-5] Lundwall A, Band V, Blaber M, Clements JA, Courty Y, Diamandis EP, et al. (June 2006). "A comprehensive nomenclature for serine proteases with homology to tissue kallikreins". Biological Chemistry. 387 (6): 637–41. doi:10.1515/BC.2006.082. PMID 16800724. S2CID 436200.

[pmid16800723-6] "Proceedings of the 1st International Symposium on Kallikreins, Lausanne, Switzerland, September 1-3 , 2005". Biological Chemistry. 387 (6): 635–824. June 2006. doi:10.1515/BC.2006.081. PMID 16800723. S2CID 83910246.

[entrez-7] "Entrez Gene: KLK14 kallikrein-related peptidase 14".

[8] Prassas I, Eissa A, Poda G, Diamandis EP (March 2015). "Unleashing the therapeutic potential of human kallikrein-related serine proteases". Nature Reviews. Drug Discovery. 14 (3): 183–202. doi:10.1038/nrd4534. PMID 25698643. S2CID 38090565.

[9] Emami N, Diamandis EP (December 2007). "New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family". Molecular Oncology. 1 (3): 269–87. doi:10.1016/j.molonc.2007.09.003. PMC 5543873. PMID 19383303.

[10] Brattsand M, Stefansson K, Lundh C, Haasum Y, Egelrud T (January 2005). "A proteolytic cascade of kallikreins in the stratum corneum". The Journal of Investigative Dermatology. 124 (1): 198–203. doi:10.1111/j.0022-202x.2004.23547.x. PMID 15654974.

[11] Eissa A, Diamandis EP (June 2008). "Human tissue kallikreins as promiscuous modulators of homeostatic skin barrier functions". Biological Chemistry. 389 (6): 669–80. doi:10.1515/bc.2008.079. PMID 18627299. S2CID 30602024.

[12] Hachem JP, Man MQ, Crumrine D, Uchida Y, Brown BE, Rogiers V, et al. (September 2005). "Sustained serine proteases activity by prolonged increase in pH leads to degradation of lipid processing enzymes and profound alterations of barrier function and stratum corneum integrity". The Journal of Investigative Dermatology. 125 (3): 510–20. doi:10.1111/j.0022-202x.2005.23838.x. PMID 16117792.

[13] Hachem JP, Wagberg F, Schmuth M, Crumrine D, Lissens W, Jayakumar A, et al. (July 2006). "Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome". The Journal of Investigative Dermatology. 126 (7): 1609–21. doi:10.1038/sj.jid.5700288. PMID 16601670.

[14] Swedberg JE, Veer SJ, Harris JM (2012). "Natural, engineered and synthetic inhibitors of kallikrein-related peptidases.". In Magdolen V, Sommerhoff CP, Fritz H, Schmitt M (eds.). Kallikrein-Related Peptidases. Vol. 1: Characterization, regulation, and interactions within the proteas e. Walter de Gruyter GmbH. pp. 141–160. doi:10.1515/9783110260373.141. ISBN 978-3-11-026037-3.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

Search

KLK14

네임스페이스

더

레퍼런스

추가 정보

외부 링크